Evogene, QUT Team Up to Target 60–70% Cisplatin Resistance in Lung Cancer
Evogene partners with Queensland University of Technology’s Dr. Mark Adams to apply its ChemPass AI toward small-molecule inhibitors targeting a novel cisplatin resistance pathway in non-small cell lung cancer. Collaboration aims to generate leads overcoming 60–70% cisplatin resistance and 30–40% targeted therapy failures in NSCLC using AI-driven multi-parameter molecular design.
1. Partnership Objectives
Evogene has entered a research collaboration with Dr. Mark Adams’ group at Queensland University of Technology to target chemotherapy-resistant non-small cell lung cancer. The partnership leverages Dr. Adams’ discovery of a druggable cisplatin detoxification pathway, aiming to restore treatment sensitivity by designing novel small-molecule inhibitors.
2. AI-Driven Drug Design
Using its proprietary ChemPass AI platform, Evogene will generate and prioritize compounds with strong inhibitory potential and favorable drug-like properties. Iterative integration of biological insights from QUT will guide multi-parameter optimization, focusing on overcoming 60–70% intrinsic cisplatin resistance and 30–40% targeted therapy failures in NSCLC.